Vanguard Group Inc. Trims Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Key Points

• Vanguard Group Inc. has reduced its stake in Krystal Biotech by 1.8%, now holding 2,825,282 shares, valued at approximately $509.4 million.
• GAMMA Investing LLC significantly increased its position by over 50,000% in the same quarter, owning 121,342 shares worth about $21.9 million.
• Analysts maintain a positive outlook on the stock with a consensus rating of "buy" and a target price averaging $210.75, despite some minor adjustments in target prices by various firms.

Vanguard Group Inc. decreased its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 1.8% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,825,282 shares of the company's stock after selling 53,169 shares during the quarter. Vanguard Group Inc. owned about 9.78% of Krystal Biotech worth $509,398,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. Evolutionary Tree Capital Management LLC lifted its position in shares of Krystal Biotech by 24.7% during the 1st quarter. Evolutionary Tree Capital Management LLC now owns 13,343 shares of the company's stock valued at $2,406,000 after acquiring an additional 2,643 shares during the period. Blair William & Co. IL lifted its holdings in shares of Krystal Biotech by 26.7% in the first quarter. Blair William & Co. IL now owns 9,433 shares of the company's stock valued at $1,701,000 after purchasing an additional 1,990 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in Krystal Biotech by 27.4% during the first quarter. PNC Financial Services Group Inc. now owns 2,141 shares of the company's stock worth $386,000 after acquiring an additional 461 shares during the period. Jefferies Financial Group Inc. bought a new stake in shares of Krystal Biotech in the first quarter valued at $757,000. Finally, Wealthquest Corp purchased a new position in shares of Krystal Biotech in the first quarter valued at $347,000. 86.29% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 1,389 shares of Krystal Biotech stock in a transaction on Wednesday, July 16th. The shares were sold at an average price of $150.00, for a total value of $208,350.00. Following the transaction, the insider directly owned 1,508,056 shares in the company, valued at approximately $226,208,400. The trade was a 0.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders have sold 49,800 shares of company stock worth $7,487,943. 13.70% of the stock is owned by company insiders.

Krystal Biotech Stock Performance

Shares of NASDAQ KRYS traded down $0.06 during midday trading on Friday, reaching $150.27. 238,579 shares of the stock were exchanged, compared to its average volume of 436,269. The company has a 50 day simple moving average of $143.40 and a 200 day simple moving average of $155.01. The stock has a market capitalization of $4.35 billion, a P/E ratio of 30.54 and a beta of 0.70. Krystal Biotech, Inc. has a twelve month low of $122.80 and a twelve month high of $207.84.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.21. The business had revenue of $96.04 million during the quarter, compared to analysts' expectations of $95.42 million. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. On average, research analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Guggenheim reduced their target price on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Citigroup reiterated a "neutral" rating and set a $166.00 target price (down from $176.00) on shares of Krystal Biotech in a research note on Tuesday, August 5th. HC Wainwright restated a "buy" rating and issued a $240.00 price target on shares of Krystal Biotech in a research note on Friday, July 25th. Bank of America decreased their price target on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a report on Tuesday, July 22nd. Finally, Chardan Capital restated a "buy" rating and set a $219.00 target price on shares of Krystal Biotech in a research report on Tuesday, August 5th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $210.75.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).